Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. SPY
3. AZN
4. FNGR
5. PLUR
6. EYPT
7. HIVE
8. GSAT
9. S
10. AGPU

Go back to Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration

Leerink Partners Reiterates Outperform on Regeneron (REGN)

October 3, 2016 8:48 AM EDT

Leerink Partners reiterated an Outperform rating and $530.00 price target on Regeneron Pharma (NASDAQ: REGN) after Regeneron and Sanofi reported full results from the two Phase III SOLO studies.

Analyst Geoffrey Porges commented, "We reiterate our bullish view for dupilumab after Regeneron and Sanofi (SNY, OP) reported full results from the two Phase III SOLO studies in... More

Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMD

September 30, 2016 10:16 AM EDT

Roth Capital reaffirms Regeneron (Nasdaq: REGN) at Buy with a price target of $520 following... More

Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo Data

September 30, 2016 8:05 AM EDT

Ophthotech Corp (NASDAQ: OPHT) was in focus Friday morning after Regeneron (NASDAQ: REGN) announced topline results from its Phase 2 CAPELLA study evaluating Eylea (aflibercept) co-formulated with rinucumab in patients with neovascular age-related macular degeneration (wet AMD).

Ophthotech traded lower pre-market.

... More